This article is more than 5 years old. Information may no longer be current.

CNTF shows regression of geographic atrophy size

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ATLANTA — Interim phase 2 results showed ciliary neurotrophic factor is effective in reducing the size of geographic atrophy in dry age-related macular degeneration patients.

Carmen A. Puliafito

"The new holy grail of macular degeneration therapy is a treatment to arrest the progression of geographic atrophy, which we recognize to be the most common cause of severe vision loss in patients with atrophic AMD," Carmen A. Puliafito, MD, MBA, said during the Retina Subspecialty Day preceding the annual American Academy of Ophthalmology meeting. "CNTF is a powerful cytokine which may promote rescue of retinal cells."

The area of geographic atrophy shrunk by an average of 1.3 mm² in 27 patients treated with a high dose of CNTF, he said. Macular volume increased by an average of 0.5 mm² and 0.3 mm² in the high-dose and low-dose treatment groups, respectively.

"Interim results from a phase 2 study shows promising biologic trends in decreasing area of geographic atrophy and increasing OCT macular volume," Dr. Puliafito said.